Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 81, Issue 1, Pages 171-173Publisher
WILEY-BLACKWELL
DOI: 10.1111/bcp.12761
Keywords
-
Categories
Ask authors/readers for more resources
Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer. Olaparib inhibits poly(ADP-ribose) polymerase, thereby blocking the repair of single-strand DNA breaks. This results in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
